[{"data":1,"prerenderedAt":183},["ShallowReactive",2],{"content-route-/en/research/fluconazole-resistant-vvc-management-2024":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":166,"alternates":174},"target","/en/research/fluconazole-resistant-vvc-management-2024","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":65,"body":69},"Fluconazole-resistant vaginal yeast infection: 2024 review","A narrative review maps resistance and treatment studies but offers no pooled estimate or basis for choosing a treatment.","2026-10-08","Published contextual summary of a narrative review; no treatment claim or practical action changed.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":41,"limitations":48,"practicalChange":64},"akinosoglou-fluconazole-resistant-vvc-2024","Narrative literature review","Heterogeneous published studies of vaginal yeast infection, recurrent VVC, and fluconazole-resistant Candida; the review does not define one participant population.","Sixteen articles on management of fluconazole-resistant clinical cases were included; the review has no single patient denominator or newly recruited cohort.","contextual","The review maps selected resistance and treatment reports but has no protocol-led systematic method, risk-of-bias appraisal, or pooled estimate. Its varied populations, resistance definitions, and outcomes do not establish a treatment comparison or replace the guidance and broader evidence behind the linked map.","/en/research/evidence/recurrent-vaginal-yeast-symptoms","The authors report that the research received no external funding.","The authors declared no conflicts of interest.","2024-12-04",[38,39,40],"The authors searched PubMed, MEDLINE, and Cochrane for records from 1 January 2000 through 1 September 2024. They screened 933 records and included 16 articles on clinical management of fluconazole-resistant cases; the review reports no pooled treatment estimate.","A retrospective US study summarized in Table 2 reports boric-acid mycological cure of 85.7% and clinical cure of 73.7%. The row reports 71/970 patients (7.3%) as clinically resistant, but the review does not give the denominator behind either cure percentage; this is not a randomized comparison.","The discussion mentions approximately 60% relapse after maintenance stops. It gives no numerator, denominator, defined population, maintenance regimen, or follow-up time point for this figure; it is not a new estimate from the review.",{"appliesTo":42,"doesNotApplyTo":45},[43,44],"A broad overview of selected published reports on fluconazole resistance and management in vaginal yeast infection.","Understanding why resistance methods, study populations, and reported outcomes vary across the literature.",[46,47],"Estimating an individual's likelihood of resistance or the prevalence of resistance in the United States, Poland, or another setting.","Choosing a treatment, establishing current product availability or safety, or deciding whether a particular person's symptoms are caused by resistant Candida.",[49,52,55,58,61],{"finding":50,"limitation":51},"The review searched PubMed, MEDLINE, and Cochrane from 1 January 2000 through 1 September 2024, included English-language work published since 2002, and selected 16 management articles.","It reports no protocol or registration, formal risk-of-bias appraisal, or quantitative synthesis; the limited databases, date boundary, and language restriction may omit relevant work.",{"finding":53,"limitation":54},"Included studies used different populations and methods to define resistance, including laboratory susceptibility testing, symptoms, and a commercial kit.","Some reports concern acute VVC or clinically defined resistance rather than a consistent cohort of confirmed fluconazole-resistant infection; their findings cannot be treated as one comparable population.",{"finding":56,"limitation":57},"Table 2 reports 85.7% mycological and 73.7% clinical cure with boric acid in a retrospective US study.","Although the row reports 71/970 as clinically resistant, it does not provide the denominator for either outcome percentage. The study was not randomized, so these figures are not a comparative treatment effect.",{"finding":59,"limitation":60},"The discussion repeats an approximate 60% relapse figure after maintenance treatment stops.","The review gives no numerator, denominator, defined population, regimen, or time point, so this cannot serve as a standalone estimate of recurrence after maintenance.",{"finding":62,"limitation":63},"The authors describe diagnostic concerns, including possible colonization and limitations of culture and laboratory susceptibility results.","Misclassification and variation in diagnostic work-up may affect which reports represent symptomatic infection or clinically meaningful resistance.","No practical change. The review adds context about heterogeneous reports but does not establish resistance in an individual, compare treatments reliably, or support a current treatment or safety action.",[66],{"group":67,"route":33,"label":68},"evidence","Recurrent vaginal yeast symptoms evidence map",{"type":70,"value":71,"toc":162},"minimark",[72,80,86,92,98,107,113,119,125,131,137],[73,74,76],"content-section",{"section-key":10,"title":75},"Bottom line",[77,78,79],"p",{},"This 2024 narrative review collects reports about fluconazole-resistant vaginal yeast infection, but the studies are too varied for one reliable treatment estimate. Its examples cannot show which option is best or whether resistance is present in a particular person.",[73,81,83],{"section-key":11,"title":82},"Why this source matters",[77,84,85],{},"The review shows how uneven the resistant-infection literature is: studies use different resistance tests, populations, and outcome definitions. It is useful context for understanding those differences, alongside the guidance and broader evidence that anchor the linked map.",[73,87,89],{"section-key":12,"title":88},"Study type and population",[77,90,91],{},"This is a narrative review, not a clinical study or a protocol-led systematic review. It included 16 articles about management of fluconazole-resistant clinical cases. There is no single participant group or review-wide patient denominator.",[73,93,95],{"section-key":13,"title":94},"What was examined",[77,96,97],{},"The authors searched PubMed, MEDLINE, and Cochrane for work published from 1 January 2000 through 1 September 2024. They screened 933 records: 826 were excluded as out of scope or duplicates, 81 more for language or scope, and 26 reached final-stage review. Sixteen articles were included. Papers had to be in English and published since 2002; three researchers took part in selection. The review discusses different resistance assessments and treatment reports but does not assign a treatment or make a new patient comparison.",[73,99,101,104],{"section-key":14,"title":100},"Results",[77,102,103],{},"The review does not pool treatment outcomes. In one retrospective US study summarized in Table 2, it reports boric-acid mycological cure of 85.7% and clinical cure of 73.7%. The row also reports 71 of 970 patients (7.3%) as clinically fluconazole-resistant, but the review does not identify the denominator behind either boric-acid percentage. This is an uncontrolled retrospective result, not a comparison between treatments.",[77,105,106],{},"The discussion also mentions approximately 60% relapse after maintenance stops. It gives no numerator, denominator, defined population, maintenance regimen, or follow-up time point for that figure, which is not a new estimate from this review.",[73,108,110],{"section-key":15,"title":109},"Applicability",[77,111,112],{},"These findings describe a selected, mixed set of published reports. They do not establish resistance prevalence in a particular country, identify resistance in one person, or show that a reported result applies to someone with similar symptoms. The review does not establish current product availability, treatment safety, or a treatment choice for a specific setting.",[73,114,116],{"section-key":16,"title":115},"Limitations",[77,117,118],{},"The review searched three databases, restricted inclusion to English-language articles published since 2002, and reported no protocol, registration, formal risk-of-bias appraisal, or quantitative synthesis. Resistance was assessed in different ways; some included studies concerned acute infection or relied on clinical symptoms rather than a consistent laboratory definition. The authors also discuss possible colonization, incomplete diagnostic work-ups, and limits of culture and in-vitro susceptibility results. The boric-acid percentages lack outcome denominators in the review table, and the approximate 60% post-maintenance figure lacks a defined population, regimen, and time point.",[73,120,122],{"section-key":17,"title":121},"Contribution to the current conclusion",[77,123,124],{},"This source is contextual. It gathers selected reports about fluconazole-resistant VVC but does not provide a dependable pooled or comparative treatment estimate. It does not replace current guidance or the broader evidence assessment in the linked map.",[73,126,128],{"section-key":18,"title":127},"Practical change",[77,129,130],{},"No practical change. The review does not establish resistance from symptoms, recommend a treatment, or show which option is better. It also does not establish current access or safety for any medicine in a particular country.",[73,132,134],{"section-key":19,"title":133},"Funding and conflicts",[77,135,136],{},"The authors report that the research received no external funding and declare no conflicts of interest.",[73,138,140],{"section-key":20,"title":139},"Source",[77,141,142,143,147,148,155,156,161],{},"Karolina Akinosoglou, Achilleas Livieratos, Konstantinos Asimos, Francesca Donders, and Gilbert G. G. Donders. “Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management.” ",[144,145,146],"em",{},"Pharmaceutics",". 2024;16(12):1555. ",[149,150,154],"a",{"href":151,"rel":152},"https://pmc.ncbi.nlm.nih.gov/articles/PMC11678211/",[153],"nofollow","Read the original publication"," (published 4 December 2024; DOI: 10.3390/pharmaceutics16121555). Licensed under ",[149,157,160],{"href":158,"rel":159},"https://creativecommons.org/licenses/by/4.0/",[153],"CC BY 4.0","; this is an independently written summary, not a reproduction of the article or its tables.",{"title":163,"searchDepth":164,"depth":164,"links":165},"",2,[],{"sources":167,"claims":172,"safety":173},[168],{"sourceId":27,"title":169,"canonicalId":170,"canonicalUrl":151,"publisher":146,"sourceType":171,"publicationDate":36,"lastChecked":24},"Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management","PMID:39771534; DOI:10.3390/pharmaceutics16121555","other",[],[],[175,178,181],{"rel":176,"hreflang":6,"href":177},"alternate","https://candipedia.org/en/research/fluconazole-resistant-vvc-management-2024/",{"rel":176,"hreflang":179,"href":180},"pl-PL","https://candipedia.org/pl/research/oporne-na-flukonazol-vvc-leczenie-2024/",{"rel":176,"hreflang":182,"href":177},"x-default",1791487498292]